Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: GM-611; Mitemcinal-Fumarate

Latest Information Update: 22 Jan 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Biopharmaceuticals; Chugai Pharmaceutical
  • Class Antibacterials; Gastrokinetics; Irritable bowel syndrome therapies; Macrolides
  • Mechanism of Action Motilin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic gastroparesis; Gastro-oesophageal reflux; Gastroparesis; Irritable bowel syndrome

Most Recent Events

  • 28 Oct 2005 Chugai is preparing to commence phase III studies in the US with GM 611 for the treatment of diabetic gastroparesis
  • 08 Jun 2005 Data presented at the Digestive Disease Week conference (DDW-2005) have been added to the Digestive disorders therapeutic trials section
  • 22 Apr 2005 No development reported - Phase-II for Gastro-oesophageal reflux in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top